Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product.
about
Therapies for the bone in mucopolysaccharidosesNew therapeutic approaches for Krabbe disease: The potential of pharmacological chaperonesTherapies of mucopolysaccharidosis IVA (Morquio A syndrome).Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type IAzasugar inhibitors as pharmacological chaperones for Krabbe diseaseComparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptorFunctional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene deliveryTreating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.Biopharmaceutical drug targeting to the brain.Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.New biotechnological and nanomedicine strategies for treatment of lysosomal storage disordersGenetic therapy for the nervous system.Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality.Nanotechnology applied to treatment of mucopolysaccharidoses.Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers.Drug delivery in overcoming the blood-brain barrier: role of nasal mucosal graftingalpha-L-iduronidase therapy for mucopolysaccharidosis type I.Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I.In vitro characterization of an acetylcholine receptor-transferrin fusion protein for the treatment of myasthenia gravis.Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain.A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
P2860
Q26852308-B449B61C-2696-40D1-8791-4FF09E2574B9Q28068142-D3975E2C-1263-4F3B-8AA6-F36722B53E86Q34545883-85782324-D43D-46E4-A898-8431550437D3Q34621690-17297AF0-7D09-4AF2-B0A7-8F04D71D7D89Q35652295-36D3EEE8-9259-4380-A7D9-CD4604550653Q36565901-2718410A-DD6A-4599-8C07-55DDF1BE4516Q36982214-C13FA231-1D88-467D-A0DA-225711935A06Q37668227-4261E487-305B-4C1A-8104-3195C968F89EQ37671828-FEBEF85D-57B2-4E41-97FB-CF4BCA5F9EAFQ37672410-55431186-5335-452A-B937-CB4694D47F92Q37683644-2DF33BE7-FF8D-4D53-A251-6E474A051208Q37856565-5E0DB036-44F7-48B4-9C29-FBB7A5F0FBA3Q37876354-BD728B58-E07F-41EE-8D39-5916483B56DAQ38850942-E76B4419-5B4E-434C-8740-CBAD56810C54Q38947567-FD7A6290-30D2-4FE1-856B-10CD845C5C5FQ39128950-5BAF310B-6726-42EE-A6A4-4291FBA6A551Q39952328-8A57CC01-9CDF-4129-8C08-6A72A239F406Q40609634-1CEE9E7C-C7CF-412F-B107-F9431AB6F52EQ43093968-3548DFEA-5667-4D52-9401-DD6818FCB38FQ45931498-DC0ED2CB-CD8A-4DD2-A341-025C2920CD8EQ52722420-3A8FB5EA-A54F-4548-9D93-EE77240AA1CF
P2860
Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Targeting of the CNS in MPS-IH ...... uronidase fusion gene product.
@en
type
label
Targeting of the CNS in MPS-IH ...... uronidase fusion gene product.
@en
prefLabel
Targeting of the CNS in MPS-IH ...... uronidase fusion gene product.
@en
P2093
P2860
P356
P1433
P1476
Targeting of the CNS in MPS-IH ...... uronidase fusion gene product.
@en
P2093
Brandon Peacock
Mark J Osborn
Ron T McElmurry
P2860
P304
P356
10.1038/MT.2008.119
P577
2008-06-03T00:00:00Z